Pluristem Therapeutics has gained Paul-Ehrlich-Institute (PEI) approval to begin Phase I/II study for muscle regeneration in Germany. The randomized, double blind, placebo controlled study will assess the safety and efficacy of its PLX ...
Tags: Paul-Ehrlich-Institute, PEI, PLX cells